Marinus Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MRNS research report →
About the company
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD).
- CEO
- Scott N. Braunstein
- IPO
- 2014
- Employees
- 165
- HQ
- Radnor, PA, US
Price Chart
- Market Cap
- $30.37M
- P/E
- -0.21
- P/S
- 0.98
- P/B
- 1.76
- EV/EBITDA
- -0.16
- Div Yield
- 0.00%
- Gross Margin
- 93.76%
- Op Margin
- -424.30%
- Net Margin
- -456.31%
- ROE
- -213.02%
- ROIC
- -89.82%
- Revenue
- $30.99M · 21.63%
- Net Income
- $-141,405,000 · -613.59%
- EPS
- $-2.63 · -415.69%
- Op Income
- $-131,485,000
- FCF YoY
- -3.02%
- 52W High
- $10.50
- 52W Low
- $0.22
- 50D MA
- $0.43
- 200D MA
- $1.06
- Beta
- 1.26
- Avg Volume
- 1.81M
Get TickerSpark's AI analysis on MRNS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 7, 25 | Ezickson Elan | sell | 8,600 |
| Feb 11, 25 | Ezickson Elan | sell | 10,450 |
| Feb 11, 25 | Ezickson Elan | sell | 12,375 |
| Feb 11, 25 | Ezickson Elan | sell | 16,500 |
| Feb 11, 25 | Ezickson Elan | sell | 20,900 |
| Feb 11, 25 | Ezickson Elan | sell | 16,200 |
| Feb 11, 25 | Ezickson Elan | sell | 25,000 |
| Feb 11, 25 | Ezickson Elan | sell | 2,300 |
| Feb 7, 25 | Fischer Seth H. Z. | sell | 12,707 |
| Feb 11, 25 | Fischer Seth H. Z. | sell | 16,200 |
Our MRNS coverage
Recent articles, reports, and earnings notes.
No research on MRNS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MRNS report →Similar companies
Peers in the same neighborhood.